LENZ- Lenz Therapeutics, Inc.
Lenz Therapeutics, Inc. (LENZ) has 7 insiders with recent SEC Form 4 filings, including 9 buys and 6 sells. LENZ is classified in the Biotechnology industry within the Health Care sector.
Insider Ownership
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 1.05M | $6.08M | - | |
| Other | 84.2K | $487.5K | - | |
| CEO | 77.3K | $447.5K | - | |
| Other | 14.0K | $81.1K | - | |
| CFO | 12.9K | $74.6K | - |
Activity
Buys and sells only
Transactions
10 filings · page 2
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 10, 2025 | Versant Venture Capital Vi, L.P.68 | 10% Owner | Sell | 191,376 | $34.00 | $6,506,784.00 | -10.8% | +41.9% | - | |
| Jun 27, 2025 | Versant Venture Capital Vi, L.P.68 | 10% Owner | Sell | 200,000 | $30.47 | $6,093,000.00 | -10.2% | +32.6% | -80.7% | |
| Jun 20, 2025 | Versant Venture Capital Vi, L.P.68 | 10% Owner | Sell | 334,801 | $30.19 | $10,107,817.95 | -7.4% | +39.2% | -80.6% | |
| Jun 10, 2025 | Versant Venture Capital Vi, L.P.68 | 10% Owner | Sell | 350,000 | $29.00 | $10,150,000.00 | -21.9% | +41.1% | -76.6% | |
| May 14, 2024 | Chevallard Daniel R. | Chief Financial Officer | Buy | 3,188 | $15.68 | $49,987.84 | New | +47.5% | +75.8% | |
| May 13, 2024 | McCollum James W | Director | Buy | 31,332 | $15.99 | $501,092.68 | +6.3% | +45.7% | +82.0% | |
| Mar 21, 2024 | Ra Capital Management, L.P.53 | Director, 10% Owner | Buy | 998,009 | $15.03 | $15,000,075.27 | +33.1% | +20.0% | +76.0% | |
| Apr 12, 2022 | Samsara Biocapital, L.P. | 10% Owner | Buy | 424,464 | $4.08 | $1,731,068.48 | +2.6% | -21.3% | -38.9% | |
| Apr 11, 2022 | Gutry Phil | Chief Business Officer | Buy | 5,000 | $4.01 | $20,050.00 | +1.7% | -22.1% | -37.5% | |
| Jan 24, 2022 | Samsara Biocapital, L.P. | 10% Owner | Buy | 123,000 | $8.94 | $1,099,100.00 | +0.8% | -53.3% | -79.0% |